Hyperfine Still Wants $20M-$22M in 2026-Contrast Approval Is the Real Bet

Hyperfine Keeps a Modest 2026 Target While Contrast Data Builds

Hyperfine is still guiding for $20 million to $22 million in 2026 revenue, even as Q1 showed real commercial momentum. The company reported our second-highest revenue quarter to date with over 80% year-over-year revenue growth, and it has enrolled the first patient in the contrast study that could broaden Swoop's use case. That keeps HYPR in the show-me category: the revenue target looks conservative, but investors still need repeated proof that product progress is translating into durable demand.

Why the revenue target may be the floor, not the ceiling

The key upside is not just more of the same. It is a wider diagnostic story. Hyperfine has enrolled the first patient in the Contrast PMR study, which is designed to test the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI and support an FDA 510(k) submission to expand the Swoop system's intended use to include gadolinium-based contrast agents. If that path advances, contrast could make Swoop relevant in more serious diagnostic workflows rather than leaving it as a good-for-now alternative.

Contrast PMR Matters Because It Tests Real Diagnostic Utility

The study is about usefulness, not marketing

The Contrast PMR study is a prospective, multi-center clinical study planned to enroll approximately 70 patients. Its primary objective is to evaluate the visualization of brain lesions, including lesions associated with blood-brain barrier disruption with contrast at ultra-low field. Management says the work is meant to support a future FDA submission to expand the Swoop® system's intended use to include gadolinium-based contrast agents.

That is a meaningful step beyond interest or early feasibility. If contrast meaningfully improves lesion visualization, Swoop becomes easier to place in broader neurological workflows. If not, the upside case stays more speculative.

Earlier stroke software progress shows the mechanism

Last year's FDA clearance for the multi-direction DWI software sequence helps explain why this matters. Hyperfine said the update delivers clearer, higher-quality images for stroke diagnosis, with improved sensitivity for smaller strokes and better specificity in confirming true infarcts, while the original single-direction sequence remains available for the fastest urgent cases.

That is the pattern investors want to see again: product improvements that make the system more useful in specific clinical workflows. Contrast will not change the story just by existing. It has to make Swoop more necessary.

Next-Gen Swoop and Europe Matter Only If They Drive Repeat Revenue

Better hardware should increase scan frequency and renewals

The latest hardware milestone is the next-generation Swoop system, which received FDA 510(k) clearance and brought better image quality, workflow, and usability. Hyperfine also says the platform provides faster acquisition times and a better overall user experience, while existing customers may benefit from the newer Optive AI software as a standalone software upgrade.

That distinction matters. One-time shipments are fine, but the stronger case comes from repeat revenue through: - software add-ons for current users - higher-value next-gen upgrades - more scans per installed base because the workflow is easier to use

CE Marking and UKCA approval expand the opportunity, not the proof

Hyperfine has CE Marking and UKCA approval for both the next-generation Swoop® system and the latest advancement in its Optive AI™ software, which management says enable commercialization across Europe and the United Kingdom. That broadens the addressable market and supports the international growth strategy.

But regulatory approval is not the same thing as sustained demand. The next updates need to show that Europe becomes more than a regulatory win and that interest converts into placements and repeatable orders.

The market already rewarded the clearance headline

Investors reacted quickly to the next-gen clearance. After the announcement, shares rose 41% and closed at $0.85. That move suggests the market wants evidence that the hardware refresh improves commercial conversion, not just imaging specs.

What Would Confirm or Break the Story Now?

Q1 looked solid on the surface, with over 80% year-over-year revenue growth. But one strong quarter does not prove a durable pattern. The next few updates need to show that commercial momentum, product adoption, and pipeline progress are all moving together.

Five watchpoints

• Sustained sell-through: Recent demand has to keep converting into shipped systems and repeat orders, not just a one-quarter spike off a small base.
• Contrast study progress: The Contrast PMR study needs to stay on track if investors are going to keep leaning on the expected FDA pathway.
• Europe commercialization:CE Marking and UKCA approval matter only if they lead to meaningful traction for the next-generation Swoop system and Optive AI software.
• Repeat revenue signals: Upgrades, software attach, and higher utilization in the installed base should start showing up in business updates.
• Execution against timing: Hyperfine still needs to validate that product momentum is translating into real commercial utility on the company's current timeline.

For now, the position still looks best described as constructively skeptical. The target may be conservative, but the stock only works if contrast, next-gen hardware, and Europe start reinforcing each other in actual usage and revenue.